Artificial intelligence-assisted FTIR spectroscopy for hormone receptor subtyping in formalin-fixed breast cancer tissues.
AI-enhanced spectroscopy offers a faster, antibody-free way to classify breast cancer subtypes, potentially expanding molecular testing access globally.
This study validates AI-enhanced infrared spectroscopy (FTIR) as a tool for hormone receptor subtyping in fixed breast cancer tissues, demonstrating that spectroscopic signatures combined with machine learning can distinguish ER/PR/HER2 subtypes without antibody-based IHC. The approach could expand molecular subtyping access in resource-limited settings.
What the study was
- Study design
- Validation study (diagnostic AI)
- Population
- Formalin-fixed breast cancer tissue samples
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Why it surfaced
AI + spectroscopy for cancer subtyping is a novel diagnostic approach; resource equity potential; lower impact journal limits score despite topic relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.